Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)-Reference-Cited by-同舟云学术

Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)

Published:2023-08 Issue:4 Volume:8 Page:101568
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Heinrich K.,Karthaus M.,Fruehauf S.,Graeven U.,Mueller L.,König A.O.,von Weikersthal L. Fischer,Caca K.,Kretzschmar A.,Goekkurt E.,Haas S.,Alig A.H.S.,Kurreck A.,Stahler A.,Held S.,Sommerhäuser G.,Heinemann V.,Stintzing S.,Trarbach T.,Modest D.P.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference47 articles.

1. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer;Van Cutsem;Ann Oncol,2016

2. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study;Douillard;J Clin Oncol,2010

3. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial;Heinemann;Lancet Oncol,2014

4. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial;Venook;JAMA,2017

5. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer;Van Cutsem;J Clin Oncol,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Folic Acid Deficiency;Advances in Medical Diagnosis, Treatment, and Care;2024-06-14

2. Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial;International Journal of Colorectal Disease;2024-06-11

3. Temporal dynamics of RAS mutations in circulating tumor DNA in metastatic colorectal cancer: clinical significance of mutation loss during treatment;Journal of Cancer Research and Clinical Oncology;2024-05-28